Coronavirus disease 2019 and the revival of passive immunization: Antibody therapy for inhibiting severe acute respiratory syndrome coronavirus 2 and preventing host cell infection: IUPHAR review: 31.
COVID-19
SARS-CoV-2
antibody cocktail
convalescent plasma
neutralizing antibodies
Journal
British journal of pharmacology
ISSN: 1476-5381
Titre abrégé: Br J Pharmacol
Pays: England
ID NLM: 7502536
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
revised:
24
12
2020
received:
28
10
2020
accepted:
29
12
2020
pubmed:
6
1
2021
medline:
13
8
2021
entrez:
5
1
2021
Statut:
ppublish
Résumé
The coronavirus disease 2019 (COVID-19) pandemic stimulated both the scientific community and healthcare companies to undertake an unprecedented effort with the aim of understanding the molecular mechanisms of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and developing effective therapeutic solutions. The peculiar immune response triggered by this virus, which seems to last only few months, led to a search for alternatives such as passive immunization in addition to conventional vaccinations. Convalescent sera, monoclonal antibodies selected from the most potent neutralizing binders induced by the virus infection, recombinant human single-domain antibodies, and binders of variable scaffold and different origin have been tested alone or in combination exploiting monovalent, multivalent and multispecific formats. In this review, we analyse the state of the research in this field and present a summary of the ongoing projects finalized to identify suitable molecules for therapies based on passive immunization.
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
3359-3372Subventions
Organisme : Aimwell Charitable Trust
Organisme : Israel Ministry of Science and Technology
Organisme : Israel Science Foundation - Moked grant
Organisme : Javna Agencija za Raziskovalno Dejavnost RS
ID : ARRS_PA-0107
Organisme : Rosetrees Trust
Organisme : Israel Science Foundation
Informations de copyright
© 2021 The British Pharmacological Society.
Références
Accorsi, P., Berti, P., de Angelis, V., De Silvestro, G., Mascaretti, L., & Ostuni, A. (2020). Position paper on the preparation of immune plasma to be used in the treatment of patients with COVID-19. Blood Transfusion, 18, 163-166. https://doi.org/10.2450/2020.0124-20
Ahn, J. Y., Sohn, Y., Lee, S. H., Cho, Y., Hyun, J. H., Baek, Y. J., Jeong, S. J., Kim, J. H., Ku, N. S., Yeom, J.-S., Roh, J., Ahn, M. Y., Chin, B. S., Kim, Y. S., Lee, H., Yong, D., Kim, H. O., Kim, S., & Choi, J. Y. (2020). Use of convalescent plasma therapy in two COVID-19 patients with acute respiratory distress syndrome in Korea. Journal of Korean Medical Science, 35, e149. https://doi.org/10.3346/jkms.2020.35.e149
Alexander, S. P. H., Armstrong, J. F., Davenport, A. P., Davies, J. A., Faccenda, E., Harding, S. D., Levi-Schaffer, F., Maguire, J. J., Pawson, A. J., Southan, C., & Spedding, M. J. (2020). A rational roadmap for SARS-CoV-2/COVID-19 pharmacotherapeutic research and development: IUPHAR review 29. British Journal of Pharmacology, 177, 4942-4966. https://doi.org/10.1111/bph.15094
Alexander, S. P. H., Christopoulos, A., Davenport, A. P., Kelly, E., Mathie, A., Peters, J. A., Veale, E. L., Armstrong, J. F., Faccenda, E., Harding, S. D., Pawson, A. J., Sharman, J. L., Southan, C., Davies, J. A., Abbracchio, M. P., Alexander, W., Al-hosaini, K., Bäck, M., Beaulieu, J.-. M., … CGTP Collaborators. (2019). THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors. British Journal of Pharmacology, 176, S21-S141. https://doi.org/10.1111/bph.14748
Alexander, S. P. H., Fabbro, D., Kelly, E., Mathie, A., Peters, J. A., Veale, E. L., Armstrong, J. F., Faccenda, E., Harding, S. D., Pawson, A. J., Sharman, J. L., Southan, C., Davies, J. A., Bryant, C., Farndale, R. W., Hobbs, A., Jarvis, G. E., MacEwan, D., Monie, T. P., … CGTP Collaborators. (2019a). THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Catalytic receptors. British Journal of Pharmacology, 176, S247-S296. https://doi.org/10.1111/bph.14751
Alexander, S. P. H., Fabbro, D., Kelly, E., Mathie, A., Peters, J. A., Veale, E. L., Armstrong, J. F., Faccenda, E., Harding, S. D., Pawson, A. J., Sharman, J. L., Southan, C., Davies, J. A., Beuve, A., Boison, D., Brouckaert, P., Burnett, J. C., Burns, K., Dessauer, C., … CGTP Collaborators. (2019b). THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Enzymes. British Journal of Pharmacology, 176, S297-S396. https://doi.org/10.1111/bph.14752
Alexander, S. P. H., Kelly, E., Mathie, A., Peters, J. A., Veale, E. L., Faccenda, E., Harding, S. D., Pawson, A. J., Sharman, J. L., Southan, C., Buneman, O. P., Cidlowski, J. A., Christopoulos, A., Davenport, A. P., Fabbro, D., Spedding, M., Striessnig, J., Davies, J. A., Arumugam, T. V., … CGTP Collaborators. (2019). THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Other Protein Targets. British Journal of Pharmacology, 176, S1-S20. https://doi.org/10.1111/bph.14747
Alsoussi, W. B., Turner, J. S., Case, J. B., Zhao, H., Schmitz, A. J., Zhou, J. Q., Chen, R. E., Lei, T., Rizk, A. A., McIntire, K. M., Winkler, E. S., Fox, J. M., Kafai, N. M., Thackray, L. B., Hassan, A. O., Amanat, F., Krammer, F., Watson, C. T., Kleinstein, S. H., … Ellebedy, A. H. (2020). A potently neutralizing antibody protects mice against SARS-CoV-2 infection. Journal of Immunology, 205, 915-922. https://doi.org/10.4049/jimmunol.2000583
Arabi, Y. M., Hajeer, A. H., Luke, T., Raviprakash, K., Balkhy, H., Johani, S., al-Dawood, A., al-Qahtani, S., al-Omari, A., al-Hameed, F., Hayden, F. G., Fowler, R., Bouchama, A., Shindo, N., al-Khairy, K., Carson, G., Taha, Y., Sadat, M., & Alahmadi, M. (2016). Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia. Emerging Infectious Diseases, 22, 1554-1561. https://doi.org/10.3201/eid2209.151164
Arvin, A. M., Fink, K., Schmid, M. A., Cathcart, A., Spreafico, R., Havenar-Daughton, C., Lanzavecchia, A., Corti, D., & Virgin, H. W. (2020). A perspective on potential antibody-dependent enhancement of SARS-CoV-2. Nature, 584, 353-363. https://doi.org/10.1038/s41586-020-2538-8
Barnes, C. O., West, A. P. Jr., Huey-Tubman, K. E., Hoffmann, M. A. G., Sharaf, N. G., Hoffman, P. R., Koranda, N., Gristick, H. B., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Finkin, S., Hägglöf, T., Hurley, A., Millard, K. G., Weisblum, Y., Schmidt, F., Hatziioannou, T., Bieniasz, P. D., … Bjorkman, P. J. (2020). Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies. Cell, 182, 828-842, e16. https://doi.org/10.1016/j.cell.2020.06.025
Bastard, P., Rosen, L. B., Zhang, Q., Michailidis, E., Hoffmann, H. H., Zhang, Y., Dorgham, K., Philippot, Q., Rosain, J., Béziat, V., Manry, J., Shaw, E., Haljasmägi, L., Peterson, P., Lorenzo, L., Bizien, L., Trouillet-Assant, S., Dobbs, K., de Jesus, A. A., … COVID Human Genetic Effort§. (2020). Auto-antibodies against type I IFNs in patients with life-threatening COVID-19. Science, 370, eabd4585. https://doi.org/10.1126/science.abd4585
Bentivegna, E., Sentimentale, A., Luciani, M., Speranza, M. L., Guerritore, L., & Martelletti, P. (2020). New IgM seroconversion and positive RT-PCR test after exposure to the virus in recovered COVID-19 patient. Journal of Medical Virology, 93, 97-98. https://doi.org/10.1002/jmv.26160
Bloch, E. M., Shoham, S., Casadevall, A., Sachais, B. S., Shaz, B., Winters, J. L., van Buskirk, C., Grossman, B. J., Joyner, M., Henderson, J. P., Pekosz, A., Lau, B., Wesolowski, A., Katz, L., Shan, H., Auwaerter, P. G., Thomas, D., Sullivan, D. J., Paneth, N., … Tobian, A. A. R. (2020). Deployment of convalescent plasma for the prevention and treatment of COVID-19. The Journal of Clinical Investigation, 130, 2757-2765. https://doi.org/10.1172/JCI138745
Bracken, C. J., Lim, S. A., Solomon, P., Rettko, N. J., Nguyen, D. P., Zha, B. S., Schaefer, K., Byrnes, J. R., Zhou, J., Lui, I., & Liu, J. (2021). Bi-paratopic and multivalent human VH domains neutralize SARS-CoV-2 by targeting distinct epitopes within the ACE2 binding interface of Spike. Nature Chemical Biology, 17, 113-121. https://doi.org/10.1038/s41589-020-00679-1
Brouwer, P. J. M., Caniels, T. G., van der Straten, K., Snitselaar, J. L., Aldon, Y., Bangaru, S., Torres, J. L., Okba, N. M. A., Claireaux, M., Kerster, G., Bentlage, A. E. H., van Haaren, M. M., Guerra, D., Burger, J. A., Schermer, E. E., Verheul, K. D., van der Velde, N., van der Kooi, A., van Schooten, J., … van Gils, M. J. (2020). Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science, 369, 643-650. https://doi.org/10.1126/science.abc5902
Cao, Y., Su, B., Guo, X., Sun, W., Deng, Y., Bao, L., Zhu, Q., Zhang, X., Zheng, Y., Geng, C., Chai, X., He, R., Li, X., Lv, Q., Zhu, H., Deng, W., Xu, Y., Wang, Y., Qiao, L., … Xie, X. S. (2020). Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell, 182, 73-84, e16. https://doi.org/10.1016/j.cell.2020.05.025
Carfì, A., Bernabei, R., Landi, F., & Gemelli against COVID-19 post-acute care study group. (2020). Persistent symptoms in patients after acute COVID-19. JAMA, 324, 603-605. https://doi.org/10.1001/jama.2020.12603
Cegolon, L., Pichierri, J., Mastrangelo, G., Cinquetti, S., Sotgiu, G., Bellizzi, S., & Pichierri, G. (2020). Hypothesis to explain the severe form of COVID-19 in Northern Italy. BMJ Global Health, 5, e002564. https://doi.org/10.1136/bmjgh-2020-002564
Chen, W. H., Hotez, P. J., & Bottazzi, M. E. (2020). Potential for developing a SARS-CoV receptor-binding domain (RBD) recombinant protein as a heterologous human vaccine against coronavirus infectious disease (COVID)-19. Human Vaccines & Immunotherapeutics, 16, 1239-1242. https://doi.org/10.1080/21645515.2020.1740560
Cheng, Y., Wong, R., Soo, Y. O., Wong, W. S., Lee, C. K., Ng, M. H., Chan, P., Wong, K. C., Leung, C. B., & Cheng, G. (2005). Use of convalescent plasma therapy in SARS patients in Hong Kong. European Journal of Clinical Microbiology & Infectious Diseases, 24, 44-46. https://doi.org/10.1007/s10096-004-1271-9
Chi, X., Liu, X., Wang, C., Zhang, X., Li, X., Hou, J., Ren, L., Jin, Q., Wang, J., & Yang, W. (2020). Humanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain. Nature Communications, 11, 4528. https://doi.org/10.1038/s41467-020-18387-8
Criado, P. R., Pincelli, T. P. H., Criado, R. F. J., Abdalla, B. M. Z., & Belda Junior, W. (2020). Potential interactions of SARS-CoV-2 with human cell receptors in the skin: Understanding the enigma for a lower frequency of skin lesions compared to other tissues. Experimental Dermatology, 29, 936-944. https://doi.org/10.1111/exd.14186
de Marco, A. (2020). Recombinant expression of nanobodies and nanobody-derived immunoreagents. Protein Expression and Purification, 172, 105645. https://doi.org/10.1016/j.pep.2020.105645
Deng, W., Bao, L., Liu, J., Xiao, C., Liu, J., Xue, J., Lv, Q., Qi, F., Gao, H., Yu, P., Xu, Y., Qu, Y., Li, F., Xiang, Z., Yu, H., Gong, S., Liu, M., Wang, G., Wang, S., … Qin, C. (2020). Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques. Science, 369, 818-823. https://doi.org/10.1126/science.abc5343
Dong, J., Huang, B., Jia, Z., Wang, B., Kankanamalage, S. G., Titong, A., & Liu, Y. (2020). Development of multi-specific humanized llama antibodies blocking SARS-CoV-2/ACE2 interaction with high affinity and avidity. Emerging Microbes & Infections, 9, 1034-1036. https://doi.org/10.1080/22221751.2020.1768806
Duan, K., Liu, B., Li, C., Zhang, H., Yu, T., Qu, J., Zhou, M., Chen, L., Meng, S., Hu, Y., Peng, C., Yuan, M., Huang, J., Wang, Z., Yu, J., Gao, X., Wang, D., Yu, X., Li, L., … Yang, X. (2020). Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proceedings of the National Academy of Sciences, 117, 9490-9496. https://doi.org/10.1073/pnas.2004168117
Eckhardt, C. M., Cummings, M. J., Rajagopalan, K. N., Borden, S., Bitan, Z. C., Wolf, A., Kantor, A., Briese, T., Meyer, B. J., Jacobson, S. D., Scotto, D., Mishra, N., Philip, N. M., Stotler, B. A., Schwartz, J., Shaz, B., Spitalnik, S. L., Eisenberger, A., Hod, E. A., … Scotto, D. (2020). Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial. Trials, 21, 499. https://doi.org/10.1186/s13063-020-04422-y
Edridge, A. W., Kaczorowska, J. M., Hoste, A. C., Bakker, M., Klein, M., & Jebbink, M. F. (2020). Coronavirus protective immunity is short-lasting. Nature Medicine, 26(11), 1691-1693. https://doi.org/10.1038/s41591-020-1083-1
Faccenda, E., Armstrong, J., Davenport, A., Harding, S., Pawson, A., Southan, C., & Davies, J. (2020). Coronavirus information. IUPHAR/BPS Guide to Pharmacology. Retrieved from https://www.guidetopharmacology.org/coronavirus.jsp
Gousseff, M., Penot, P., Gallay, L., Batisse, D., Benech, N., Bouiller, K., Collarino, R., Conrad, A., Slama, D., Joseph, C., Lemaignen, A., Lescure, F. X., Levy, B., Mahevas, M., Pozzetto, B., Vignier, N., Wyplosz, B., Salmon, D., Goehringer, F., … in behalf of the COCOREC study group. (2020). Clinical recurrences of COVID-19 symptoms after recovery: Viral relapse, reinfection or inflammatory rebound? The Journal of Infection, 81, 816-846. https://doi.org/10.1016/j.jinf.2020.06.073
Grant, M. C., Geoghegan, L., Arbyn, M., Mohammed, Z., McGuinness, L., Clarke, E. L., & Wade, R. (2020). The prevalence of symptoms in 24,410 adults infected by the novel coronavirus (SARS-CoV-2; COVID-19): A systematic review and meta-analysis of 148 studies from 9 countries. PLoS ONE, 15, e0234765. https://doi.org/10.1371/journal.pone.0234765
Hanke, L., Vidakovics Perez, L., Sheward, D. J., Das, H., Schulte, T., Moliner-Morro, A., Corcoran, M., Achour, A., Karlsson Hedestam, G. B., Hällberg, B. M., Murrell, B., & McInerney, G. M. (2020). An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction. Nature Communications, 11, 4420. https://doi.org/10.1038/s41467-020-18174-5
Hansen, J., Baum, A., Pascal, K. E., Russo, V., Giordano, S., Wloga, E., Fulton, B. O., Yan, Y., Koon, K., Patel, K., Chung, K. M., Hermann, A., Ullman, E., Cruz, J., Rafique, A., Huang, T., Fairhurst, J., Libertiny, C., Malbec, M., … Kyratsous, C. A. (2020). Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science, 369, 1010-1014. https://doi.org/10.1126/science.abd0827
Hansson, M., Ringdahl, J., Robert, A., Power, U., Goetsch, L., Nguyen, T. N., Uhlén, M., Ståhl, S., & Nygren, P. Å. (1999). An in vitro selected binding protein (affibody) shows conformation-dependent recognition of the respiratory syncytial virus (RSV) G protein. Immunotechnology, 4, 237-252. https://doi.org/10.1016/S1380-2933(98)00026-8
Harmsen, M. M., van Solt, C. B., van Zijderveld-van Bemmel, A. M., Niewold, T. A., & van Zijderveld, F. G. (2007). Selection and optimization of proteolytically stable llama single-domain antibody fragments for oral immunotherapy. Applied Microbiology and Biotechnology, 72, 544-551. https://doi.org/10.1007/s00253-005-0300-7
Hart, T. K., Cook, R. M., Zia-Amirhosseini, P., Minthorn, E., Sellers, T. S., Maleeff, B. E., Eustis, S., Schwartz, L. W., Tsui, P., Appelbaum, E. R., Martin, E. C., Bugelski, P. J., & Herzyk, D. J. (2001). Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys. The Journal of Allergy and Clinical Immunology, 108, 250-257. https://doi.org/10.1067/mai.2001.116576
He, Y., Li, J., Heck, S., Lustigman, S., & Jiang, S. (2006). Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: Implication for vaccine design. Journal of Virology, 80, 5757-5767. https://doi.org/10.1128/JVI.00083-06
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N. H., Nitsche, A., Müller, M. A., Drosten, C., & Pöhlmann, S. (2020). SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell, 181, 271-280.e8. https://doi.org/10.1016/j.cell.2020.02.052
Huang, A. T., Garcia-Carreras, B., Hitchings, M. D., Yang, B., Katzelnick, L. C., Rattigan, S. M., Borgert, B. A., Moreno, C. A., Solomon, B. D., Rodriguez-Barraquer, I., Lessler, J., Salje, H., Burke, D., Wesolowski, A., & Cummings, D. A. (2020). A systematic review of antibody mediated immunity to coronaviruses: Antibody kinetics, correlates of protection, and association of antibody responses with severity of disease. Nature Communications, 11, 4704. https://doi.org/10.1038/s41467-020-18450-4
Huo, J., Le Bas, A., Ruza, R. R., Duyvesteyn, H. M. E., Mikolajek, H., Malinauskas, T., Tan, T. K., Rijal, P., Dumoux, M., Ward, P. N., Ren, J., Zhou, D., Harrison, P. J., Weckener, M., Clare, D. K., Vogirala, V. K., Radecke, J., Moynié, L., Zhao, Y., … Naismith, J. H. (2020). Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2. Nature Structural & Molecular Biology, 27, 846-854. https://doi.org/10.1038/s41594-020-0469-6
Jacob, C. O. (2020). On the genetics and immunopathogenesis of COVID-19. Clinical Immunology, 220, 108591. https://doi.org/10.1016/j.clim.2020.108591
Kirkcaldy, R. D., King, B. A., & Brooks, J. T. (2020). COVID-19 and postinfection immunity: Limited evidence, many remaining questions. JAMA, 323, 2245-2246. https://doi.org/10.1001/jama.2020.7869
Klasse, P. J., & Moore, J. P. (2020). Antibodies to SARS-CoV-2 and their potential for therapeutic passive immunization. eLife, 9, e57877. https://doi.org/10.7554/eLife.57877
Kleine-Weber, H., Elzayat, M. T., Wang, L., Graham, B. S., Müller, M. A., Drosten, C., Pöhlmann, S., & Hoffmann, M. (2019). Mutations in the spike protein of Middle East respiratory syndrome coronavirus transmitted in Korea increase resistance to antibody-mediated neutralization. Journal of Virology, 93, e01381-18. https://doi.org/10.1128/JVI
Lei, C., Qian, K., Li, T., Zhang, S., Fu, W., Ding, M., & Hu, S. (2020). Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig. Nature Communications, 11, 2070. https://doi.org/10.1038/s41467-020-16048-4
Li, L., Zhang, W., Hu, Y., Tong, X., Zheng, S., Yang, J., Kong, Y., Ren, L., Wei, Q., Mei, H., Hu, C., Tao, C., Yang, R., Wang, J., Yu, Y., Guo, Y., Wu, X., Xu, Z., Zeng, L., … Liu, Z. (2020). Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: A randomized clinical trial. JAMA, 324, 1-11. https://doi.org/10.1001/jama.2020.10044
Liu, L., Wang, P., Nair, M. S., Yu, J., Rapp, M., Wang, Q., Luo, Y., Chan, J. F. W., Sahi, V., Figueroa, A., Guo, X. V., Cerutti, G., Bimela, J., Gorman, J., Zhou, T., Chen, Z., Yuen, K. Y., Kwong, P. D., Sodroski, J. G., … Ho, D. D. (2020). Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature, 584, 450-456. https://doi.org/10.1038/s41586-020-2571-7
Long, Q. X., Tang, X. J., Shi, Q. L., Li, Q., Deng, H. J., Yuan, J., Hu, J. L., Xu, W., Zhang, Y., Lv, F. J., Su, K., Zhang, F., Gong, J., Wu, B., Liu, X. M., Li, J. J., Qiu, J. F., Chen, J., & Huang, A. L. (2020). Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nature Medicine, 26, 1200-1204. https://doi.org/10.1038/s41591-020-0965-6
Mair-Jenkins, J., Saavedra-Campos, M., Baillie, J. K., Cleary, P., Khaw, F. M., Lim, W. S., Makki, S., Rooney, K. D., Nguyen-Van-Tam, J. S., Beck, C. R., & Convalescent Plasma Study Group. (2015). The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: A systematic review and exploratory meta-analysis. The Journal of Infectious Diseases, 211, 80-90. https://doi.org/10.1093/infdis/jiu396
Meyer, B., Drosten, C., & Müller, M. A. (2014). Serological assays for emerging coronaviruses: Challenges and pitfalls. Virus Research, 194, 175-183. https://doi.org/10.1016/j.virusres.2014.03.018
Miao, X., Luo, Y., Huang, X., Lee, S. M. Y., Yuan, Z., Tang, Y., Chen, L., Wang, C., Wu, F., Xu, Y., Jiang, W., Gao, W., Song, X., Yan, Y., Pang, T., Chen, C., Zou, Y., Fu, W., Wan, L., … Xu, Y. (2020). A novel biparatopic hybrid antibody-ACE2 fusion that blocks SARS-CoV-2 infection: Implications for therapy. MAbs, 12, 1804241. https://doi.org/10.1080/19420862.2020.1804241
Ni, L., Ye, F., Cheng, M. L., Feng, Y., Deng, Y. Q., Zhao, H., Wei, P., Ge, J., Gou, M., Li, X., Sun, L., Cao, T., Wang, P., Zhou, C., Zhang, R., Liang, P., Guo, H., Wang, X., Qin, C.-F., … Dong, C. (2020). Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals. Immunity, 52, 971-977e3. https://doi.org/10.1016/j.immuni.2020.04.023
Olichon, A., Schweizer, D., Muyldermans, S., & de Marco, A. (2007). Heating represents a rapid purification method for recovering correctly folded thermo tolerant VH and VHH domains. BMC Biotechnology, 7, 7. https://doi.org/10.1186/1472-6750-7-7
Paiva, K. J., Grisson, R. D., Chan, P. A., Huard, R. C., Caliendo, A. M., Lonks, J. R., King, E., Tang, E. W., Pytel-Parenteau, D. L., Nam, G. H., Yakirevich, E., & Lu, S. (2020). Validation and performance comparison of three SARS-CoV-2 antibody assays. Journal of Medical Virology, 93(2), 916-923. https://doi.org/10.1002/jmv.26341
Pascal, K. E., Dudgeon, D., Trefry, J. C., Anantpadma, M., Sakurai, Y., Murin, C. D., Turner, H. L., Fairhurst, J., Torres, M., Rafique, A., Yan, Y., Badithe, A., Yu, K., Potocky, T., Bixler, S. L., Chance, T. B., Pratt, W. D., Rossi, F. D., Shamblin, J. D., … Kyratsous, C. A. (2018). Development of clinical-stage human monoclonal antibodies that treat advanced Ebola virus disease in nonhuman primates. The Journal of Infectious Diseases, 218, S612-S626. https://doi.org/10.1093/infdis/jiy285
Perley, C. C., Brocato, R. L., Wu, H., Bausch, C., Karmali, P. P., Vega, J. B., Cohen, M. V., Somerville, B., Kwilas, S. A., Principe, L. M., Shamblin, J., Chivukula, P., Sullivan, E., & Hooper, J. W. (2020). Anti-HFRS human IgG produced in transchromosomic bovines has potent hantavirus neutralizing activity and is protective in animal models. Frontiers in Microbiology, 11, 832. https://doi.org/10.3389/fmicb.2020.00832
Pinto, D., Park, Y. J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., De Marco, A., & Peter, A. (2020). Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature, 583, 290-295. https://doi.org/10.1038/s41586-020-2349-y
Prabakaran, P., Zhu, Z., Xiao, X., Biragyn, A., Dimitrov, A. S., Broder, C. C., & Dimitrov, D. S. (2009). Potent human monoclonal antibodies against SARS CoV, Nipah and Hendra viruses. Expert Opinion on Biological Therapy, 9, 355-368. https://doi.org/10.1517/14712590902763755
Prado-Vivar, B., Becerra-Wong, M., Guadalupe, J. J., Márquez, S., Gutierrez, B., Rojas-Silva, P., Grunauer, M., Trueba, G., Barragán, V., Cárdenas, P. (2020). A case of SARS-CoV-2 reinfection in Ecuador. The Lancet Infectious Diseases, https://doi.org/10.1016/s1473-3099(20)30910-5
Premkumar, L., Segovia-Chumbez, B., Jadi, R., Martinez, D. R., Raut, R., Markmann, A., Cornaby, C., Bartelt, L., Weiss, S., Park, Y., Edwards, C. E., Weimer, E., Scherer, E. M., Rouphael, N., Edupuganti, S., Weiskopf, D., Tse, L. V., Hou, Y. J., Margolis, D., … de Silva, A. M. (2020). The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Science Immunology, 5, eabc8413. https://doi.org/10.1126/sciimmunol.abc8413
Reynard, O., Jacquot, F., Evanno, G., Mai, H. L., Salama, A., Martinet, B., Duvaux, O., Bach, J. M., Conchon, S., Judor, J. P., Perota, A., Lagutina, I., Duchi, R., Lazzari, G., le Berre, L., Perreault, H., Lheriteau, E., Raoul, H., Volchkov, V., … Soulillou, J. P. (2016). Anti-EBOV GP IgGs lacking α1-3-galactose and neu5gc prolong survival and decrease blood viral load in EBOV-infected guinea pigs. PLoS One, 11, e0156775. https://doi.org/10.1371/journal.pone.0156775
Robbiani, D. F., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Wang, Z., Cho, A., Agudelo, M., Barnes, C. O., Gazumyan, A., Finkin, S., Hägglöf, T., Oliveira, T. Y., Viant, C., Hurley, A., Hoffmann, H.-H., Millard, K. G., Kost, R. G., Cipolla, M., Gordon, K., … Nussenzweig, M. C. (2020). Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature, 584, 437-442. https://doi.org/10.1038/s41586-020-2456-9
Rogers, T. F., Zhao, F., Huang, D., Beutler, N., Burns, A., He, W. T., Limbo, O., Smith, C., Song, G., Woehl, J., Yang, L., Abbott, R. K., Callaghan, S., Garcia, E., Hurtado, J., Parren, M., Peng, L., Ramirez, S., Ricketts, J., … Burton, D. R. (2020). Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science, 369, 956-963. https://doi.org/10.1126/science.abc7520
Saphire, E. O., Schendel, S. L., Gunn, B. M., Milligan, J. C., & Alter, G. (2018). Antibody-mediated protection against Ebola virus. Nature Immunology, 19, 1169-1178. https://doi.org/10.1038/s41590-018-0233-9
Sargiacomo, C., Sotgia, F., & Lisanti, M. P. (2020). COVID-19 and chronological aging: Senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection? Aging, 12, 6511-6517. https://doi.org/10.18632/aging.103001
Schoof, M., Faust, B., Saunders, R. A., Sangwan, S., Rezelj, V., Hoppe, N., Boone, M., Billesbølle, C. B., Zimanyi, M., Deshpande, I., Liang, J., Anand, A. A., Dobzinski, N., Zha, B. S., Barsi-Rhyne, B., Belyy, V., Barile-Hill, A. W., Gupta, S., Simoneau, C. R., … Manglik, A. (2020). An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation. Science, 370, 1473-1479. https://doi.org/10.1126/science.abe3255
Schweizer, A., Rusert, P., Berlinger, L., Ruprecht, C. R., Mann, A., Corthésy, S., Turville, S. G., Aravantinou, M., Fischer, M., Robbiani, M., Amstutz, P., & Trkola, A. (2008). CD4-specific designed ankyrin repeat proteins are novel potent HIV entry inhibitors with unique characteristics. PLoS Pathogens, 4, e1000109. https://doi.org/10.1371/journal.ppat.1000109
Selvaraj, V., Herman, K., & Dapaah-Afriyie, K. (2020). Severe, symptomatic reinfection in a patient with COVID-19. R.I. Medical Journal, 103, 24-26. Retrieved from https://pubmed.ncbi.nlm.nih.gov/33172223/
Shah, V. K., Firmal, P., Alam, A., Ganguly, D., & Chattopadhyay, S. (2020). Overview of immune response during SARS-CoV-2 infection: Lessons from the past. Frontiers in Immunology, 11, 1949. https://doi.org/10.3389/fimmu.2020.01949
Shen, C., Wang, Z., Zhao, F., Yang, Y., Li, J., Yuan, J., Wang, F., Li, D., Yang, M., Xing, L., Wei, J., Xiao, H., Yang, Y., Qu, J., Qing, L., Chen, L., Xu, Z., Peng, L., Li, Y., … Liu, L. (2020). Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA, 323, 1582-1589. https://doi.org/10.1001/jama.2020.4783
Shi, R., Shan, C., Duan, X., Chen, Z., Liu, P., Song, J., Song, T., Bi, X., Han, C., Wu, L., Gao, G., Hu, X., Zhang, Y., Tong, Z., Huang, W., Liu, W. J., Wu, G., Zhang, B., Wang, L., … Yan, J. (2020). A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature, 584, 120-124. https://doi.org/10.1038/s41586-020-2381-y
Škrlec, K., Štrukelj, B., & Berlec, A. (2015). Non-immunoglobulin scaffolds: A focus on their targets. Trends in Biotechnology, 33, 408-418. https://doi.org/10.1016/j.tibtech.2015.03.012
Soo, Y. O., Cheng, Y., Wong, R., Hui, D. S., Lee, C. K., Tsang, K. K., Ng, M. H. L., Chan, P., Cheng, G., & Sung, J. J. (2004). Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clinical Microbiology and Infection, 10, 676-678. https://doi.org/10.1111/j.1469-0691.2004.00956.x
Stalin Raj, V., Okba, N. M. A., Gutierrez-Alvarez, J., Drabek, D., van Dieren, B., Widagdo, W., Lamers, M. M., Widjaja, I., Fernandez-Delgado, R., Sola, I., Bensaid, A., Koopmans, M. P., Segalés, J., Osterhaus, A. D. M. E., Bosch, B. J., Enjuanes, L., & Haagmans, B. L. (2018). Chimeric camel/human heavy-chain antibodies protect against MERS-CoV infection. Science Advances, 4, eaas9667. https://doi.org/10.1126/sciadv.aas9667
Sun, Z., Chen, C., Li, W., Martinez, D. R., Drelich, A., Baek, D. S., Liu, X., Mellors, J. W., Tseng, C. T., Baric, R. S., & Dimitrov, D. S. (2020). Potent neutralization of SARS-CoV-2 by human antibody heavy-chain variable domains isolated from a large library with a new stable scaffold. MAbs, 12, 1778435. https://doi.org/10.1080/19420862.2020.1778435
Tang, Y., Liu, J., Zhang, D., Xu, Z., Ji, J., & Wen, C. (2020). Cytokine storm in COVID-19: The current evidence and treatment strategies. Frontiers in Immunology, 11, 1708. https://doi.org/10.3389/fimmu.2020.01708
Tian, X., Li, C., Huang, A., Xia, S., Lu, S., Shi, Z., Lu, L., Jiang, S., Yang, Z., Wu, Y., & Ying, T. (2020). Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerging Microbes & Infections, 9, 382-385. https://doi.org/10.1080/22221751.2020.1729069
Tillett, R. L., Sevinsky, J. R., Hartley, P. D., Kerwin, H., Crawford, N., Gorzalski, A., Laverdure, C., Verma, S. C., Rossetto, C. C., Jackson, D., & Farrell, M. J. (2020). Genomic evidence for reinfection with SARS-CoV-2: A case study. The Lancet Infectious Diseases, 21(1), 52. https://doi.org/10.1016/S1473-3099(20)30764-7
To, K. K., Hung, I. F., Ip, J. D., Chu, A. W., Chan, W. M., Tam, A. R., Fong, C. H.-Y., Yuan, S., Tsoi, H.-W., Ng, A. C.-K., Lee, L. L.-Y., Wan, P., Tso, E., To, W.-K., Tsang, D., Chan, K.-H., Huang, J.-D., Kok, K.-H., Cheng, V. C.-C., & Yuen, K.-Y. (2020). COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing. Clinical Infectious Diseases, ciaa1275. https://doi.org/10.1093/cid/ciaa1275
Torres, D. A., Ribeiro, L. D. C. B., Riello, A. P. F. L., Horovitz, D. D. G., Pinto, L. F. R., & Croda, J. (2021). Reinfection of COVID-19 after 3 months with a distinct and more aggressive clinical presentation: Case report. Journal of Medical Virology, 93(4), 1857-1859. https://doi.org/10.1002/jmv.26637
Tortorici, M. A., Beltramello, M., Lempp, F. A., Pinto, D., Dang, H. V., Rosen, L. E., McCallum, M., Bowen, J., Minola, A., Jaconi, S., Zatta, F., De Marco, A., Guarino, B., Bianchi, S., Lauron, E. J., Tucker, H., Zhou, J., Peter, A., Havenar-Daughton, C., … Veesler, D. (2020). Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms. Science, 370, 950-957. https://doi.org/10.1126/science.abe3354
Traggiai, E., Becker, S., Subbarao, K., Kolesnikova, L., Uematsu, Y., Gismondo, M. R., Murphy, B. R., Rappuoli, R., & Lanzavecchia, A. (2004). An efficient method to make human monoclonal antibodies from memory B cells: Potent neutralization of SARS coronavirus. Nature Medicine, 10, 871-875. https://doi.org/10.1038/nm1080
Tuccori, M., Ferraro, S., Convertino, I., Cappello, E., Valdiserra, G., Blandizzi, C., Maggi, F., & Focosi, D. (2020). Anti-SARS-CoV-2 neutralizing monoclonal antibodies: Clinical pipeline. MAbs, 12, 1854149. https://doi.org/10.1080/19420862.2020.1854149
Van Elslande, J., Decru, B., Jonckheere, S., Van Wijngaerden, E., Houben, E., Vandecandelaere, P., Indevuyst, C., Depypere, M., Desmet, S., André, E., Van Ranst, M., Lagrou, K., & Vermeersch, P. (2020). Antibody response against SARS-CoV-2 spike protein and nucleoprotein evaluated by four automated immunoassays and three ELISAs. Clinical Microbiology and Infection, 26(11), 1557-e1. https://doi.org/10.1016/j.cmi.2020.07.038
Van Elslande, J., Vermeersch, P., Vandervoort, K., Wawina-Bokalanga, T., Vanmechelen, B., Wollants, E., Laenen, L., André, E., Van Ranst, M., Lagrou, K., & Maes, P. (2020). Symptomatic SARS-CoV-2 reinfection by a phylogenetically distinct strain. Clinical Infectious Diseases, ciaa1330. https://doi.org/10.1093/cid/ciaa1330
Van Heeke, G., Allosery, K., De Brabandere, V., De Smedt, T., Detalle, L., & de Fougerolles, A. (2017). Nanobodies® as inhaled biotherapeutics for lung diseases. Pharmacology & Therapeutics, 169, 47-56. https://doi.org/10.1016/j.pharmthera.2016.06.012
Vitte, J., Diallo, A. B., Boumaza, A., Lopez, A., Michel, M., Allardet-Servent, J., Mezouar, S., Sereme, Y., Busnel, J.-M., Miloud, T., Malergue, F., Morange, P.-E., Halfon, P., Olive, D., Leone, M., & Mege, J.-L. (2020). A granulocytic signature identifies COVID-19 and its severity. The Journal of Infectious Diseases, 222(12), 1985-1996. https://doi.org/10.1093/infdis/jiaa591
Wan, Y., Shang, J., Sun, S., Tai, W., Chen, J., Wu, J., Shi, Z., Zhou, Y., Du, L., & Li, F. (2020). Molecular mechanism for antibody-dependent enhancement of coronavirus entry. Journal of Virology, 94, e02015-e02019. https://doi.org/10.1128/JVI.02015-19
Wang, C., Li, W., Drabek, D., Okba, N. M. A., van Haperen, R., Osterhaus, A. D., van Kuppeveld, F. J. M., Haagmans, B. L., Grosveld, F., & Bosch, B. J. (2020). A human monoclonal antibody blocking SARS-CoV-2 infection. Nature Communications, 11, 2251. https://doi.org/10.1038/s41467-020-16256-y
Wang, X., Guo, X., Xin, Q., Pan, Y., Hu, Y., Li, J., Chu, Y., Feng, Y., & Wang, Q. (2020). Neutralizing antibodies responses to SARS-CoV-2 in COVID-19 inpatients and convalescent patients. Clinical Infectious Diseases, 71, 2688-2694, ciaa721. https://doi.org/10.1093/cid/ciaa721
Wang, Y., Zhang, L., Sang, L., Ye, F., Ruan, S., Zhong, B., Song, T., Alshukairi, A. N., Chen, R., Zhang, Z., Gan, M., Zhu, A., Huang, Y., Luo, L., Mok, C. K. P., Al Gethamy, M. M., Tan, H., Li, Z., Huang, X., … Zhao, J. (2020). Kinetics of viral load and antibody response in relation to COVID-19 severity. The Journal of Clinical Investigation, 7, 138759, 5235-5244. https://doi.org/10.1172/JCI138759
Wensel, D., Sun, Y., Davis, J., Li, Z., Zhang, S., McDonagh, T., Fabrizio, D., Cockett, M., & Krystal, M. (2018). A novel gp41-binding adnectin with potent anti-HIV activity is highly synergistic when linked to a CD4-binding adnectin. Journal of Virology, 92, e00421-e00418. https://doi.org/10.1128/JVI.00421-18
Wensel, D., Sun, Y., Davis, J., Li, Z., Zhang, S., McDonagh, T., Langley, D., Mitchell, T., Tabruyn, S., Nef, P., Cockett, M., & Krystal, M. (2019). GSK3732394: A multi-specific inhibitor of HIV entry. Journal of Virology, 93, e00907-e00919. https://doi.org/10.1128/JVI.00907-19
Wensel, D., Sun, Y., Li, Z., Zhang, S., Picarillo, C., McDonagh, T., Fabrizio, D., Cockett, M., Krystal, M., & Davis, J. (2017). Discovery and characterization of a novel CD4-binding adnectin with potent anti-HIV activity. Antimicrobial Agents and Chemotherapy, 61, e00508-e00517. https://doi.org/10.1128/AAC.00508-17
West, J., Everden, S., & Nikitas, N. (2021). A case of COVID-19 reinfection in the UK. Clinical Medicine, 21(1), e52-e53. https://doi.org/10.7861/clinmed.2020-0912
Wikman, M., Rowcliffe, E., Friedman, M., Henning, P., Lindholm, L., Olofsson, S., & Ståhl, S. (2006). Selection and characterization of an HIV-1 gp120-binding affibody ligand. Biotechnology and Applied Biochemistry, 45, 93-105. https://doi.org/10.1042/BA20060016
Wrapp, D., De Vlieger, D., Corbett, K. S., Torres, G. M., Wang, N., Van Breedam, W., Roose, K., van Schie, L., VIB-CMB COVID-19 Response Team, Hoffmann, M., Pöhlmann, S., Graham, B. S., Callewaert, N., Schepens, B., Saelens, X., & McLellan, J. S. (2020). Structural basis for potent neutralization of betacoronaviruses by single-domain camelid antibodies. Cell, 181, 1004-1015e15. https://doi.org/10.1016/j.cell.2020.04.031
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C. L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020). Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science, 367, 1260-1263. https://doi.org/10.1126/science.abb2507
Wu, F., Zhao, S., Yu, B., Chen, Y. M., Wang, W., Song, Z. G., Hu, Y., Tao, Z. W., Tian, J. H., Pei, Y. Y., Yuan, M. L., Zhang, Y. L., Dai, F. H., Liu, Y., Wang, Q. M., Zheng, J. J., Xu, L., Holmes, E. C., & Zhang, Y. Z. (2020). A new coronavirus associated with human respiratory disease in China. Nature, 579, 265-269. https://doi.org/10.1038/s41586-020-2008-3
Wu, Y., Li, C., Xia, S., Tian, X., Kong, Y., Wang, Z., Gu, C., Zhang, R., Tu, C., Xie, Y., Yang, Z., Lu, L., Jiang, S., & Ying, T. (2020). Identification of human single-domain antibodies against SARS-CoV-2. Cell Host & Microbe, 27, 891-898.e5. https://doi.org/10.1016/j.chom.2020.04.023
Wu, Y., Wang, F., Shen, C., Peng, W., Li, D., Zhao, C., Li, Z., Li, S., Bi, Y., Yang, Y., Gong, Y., Xiao, H., Fan, Z., Tan, S., Wu, G., Tan, W., Lu, X., Fan, C., Wang, Q., … Liu, L. (2020). A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. Science, 368, 1274-1278. https://doi.org/10.1126/science.abc2241
Xiang, Y., Nambulli, S., Xiao, Z., Liu, H., Sang, Z., Duprex, W. P., Schneidman-Duhovny, D., Zhang, C., & Shi, Y. (2020). Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2. Science, 370, 1479-1484. https://doi.org/10.1126/science.abe4747
Yang, L., Liu, W., Wu, M., Reichert, J. M., & Ho, M. (2020). COVID-19 antibody therapeutics tracker: A global online database of antibody therapeutics for the prevention and treatment of COVID-19. Antibody Therapeutics, 3, 205-212. https://doi.org/10.1093/abt/tbaa020
Yang, Z. Y., Werner, H. C., Kong, W. P., Leung, K., Traggiai, E., Lanzavecchia, A., & Nabel, G. J. (2005). Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses. Proceedings of the National Academy of Sciences, 102, 797-801. https://doi.org/10.1073/pnas.0409065102
Ye, M., Fu, D., Ren, Y., Wang, F., Wang, D., Zhang, F., Xia, X., & Lv, T. (2020). Treatment with convalescent plasma for COVID-19 patients in Wuhan, China. Journal of Medical Virology, 92, 1890-1901. https://doi.org/10.1002/jmv.25882
Yeh, K. M., Chiueh, T. S., Siu, L. K., Lin, J. C., Chan, P. K., Peng, M. Y., Wan, H.-L., Chen, J.-H., Hu, B.-S., Perng, C.-L., Lu, J.-J., & Chang, F.-Y. (2005). Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital. The Journal of Antimicrobial Chemotherapy, 56, 919-922. https://doi.org/10.1093/jac/dki346
Yelin, D., Wirtheim, E., Vetter, P., Kalil, A. C., Bruchfeld, J., Runold, M., Guaraldi, G., Mussini, C., Gudiol, C., Pujol, M., Bandera, A., Scudeller, L., Paul, M., Kaiser, L., & Leibovici, L. (2020). Long-term consequences of COVID-19: Research needs. The Lancet Infectious Diseases, 20, 1115-1117. https://doi.org/10.1016/S1473-3099(20)30701-5
Yip, M. S., Leung, N. H., Cheung, C. Y., Li, P. H., Lee, H. H., Daëron, M., Peiris, J. S. M., Bruzzone, R., & Jaume, M. (2014). Antibody-dependent infection of human macrophages by severe acute respiratory syndrome coronavirus. Virology Journal, 11, 82. https://doi.org/10.1186/1743-422X-11-82
Zeng, Q. L., Yu, Z. J., Gou, J. J., Li, G. M., Ma, S. H., Zhang, G. F., Xu, J.-H., Lin, W.-B., Cui, G.-L., Zhang, M.-M., Li, C., Wang, Z.-S., Zhang, Z.-H., & Liu, Z.-S. (2020). Effect of convalescent plasma therapy on viral shedding and survival in patients with coronavirus disease 2019. The Journal of Infectious Diseases, 222, 38-43. https://doi.org/10.1093/infdis/jiaa228
Zhang, L., Pang, R., Xue, X., Bao, J., Ye, S., Dai, Y., Zheng, Y., Fu, Q., Hu, Z., & Yi, Y. (2020). Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19. Aging, 12, 6536-6542. https://doi.org/10.18632/aging.103102
Zhou, D., Tian, X., Qi, R., Peng, C., & Zhang, W. (2020). Identification of 22 N-glycosites on spike glycoprotein of SARS-CoV-2 and accessible surface glycopeptide motifs: Implications for vaccination and antibody therapeutics. Glycobiology, 31, 69-80. https://doi.org/10.1093/glycob/cwaa052
Zhu, S., Zhu, J., Song, Y., Chen, J., Wang, L., Zhou, M., Jiang, P., Li, W., Xue, X., Zhao, K.-N., & Zhang, L. (2018). Bispecific affibody molecule targeting HPV16 and HPV18E7 oncoproteins for enhanced molecular imaging of cervical cancer. Applied Microbiology and Biotechnology, 102, 7429-7439. https://doi.org/10.1007/s00253-018-9167-2
Zimmermann, I., Egloff, P., Hutter, C. A., Arnold, F. M., Stohler, P., Bocquet, N., Hug, M. N., Huber, S., Siegrist, M., Hetemann, L., Gera, J., Gmür, S., Spies, P., Gygax, D., Geertsma, E. R., Dawson, R. J., & Seeger, M. A. (2018). Synthetic single domain antibodies for the conformational trapping of membrane proteins. eLife, 7, e34317. https://doi.org/10.7554/eLife.34317
Zost, S. J., Gilchuk, P., Case, J. B., Binshtein, E., Chen, R. E., Nkolola, J. P., Schäfer, A., Reidy, J. X., Trivette, A., Nargi, R. S., Sutton, R. E., Suryadevara, N., Martinez, D. R., Williamson, L. E., Chen, E. C., Jones, T., Day, S., Myers, L., Hassan, A. O., … Crowe, J. E. Jr. (2020). Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature, 584, 443-449. https://doi.org/10.1038/s41586-020-2548-6
Zost, S. J., Gilchuk, P., Chen, R. E., Case, J. B., Reidy, J. X., Trivette, A., Nargi, R. S., Sutton, R. E., Suryadevara, N., Chen, E. C., Binshtein, E., Shrihari, S., Ostrowski, M., Chu, H. Y., Didier, J. E., MacRenaris, K. W., Jones, T., Day, S., Myers, L., … Crowe, J. E. Jr. (2020). Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nature Medicine, 26, 1422-1427. https://doi.org/10.1038/s41591-020-0998-x